Steve R. Ommen, M.D., director, Hypertrophic Cardiomyopathy Clinic at Mayo Clinic, reviews risk factors for sudden cardiac death in patients with hypertrophic cardiomyopathy. He introduces two risk factor identification tools appropriate for reviewing risk. Dr. Ommen emphasizes the importance of discussing implantable cardiac defibrillators in patients with hypertrophic cardiomyopathy, including risks of implantation.

If you are interested in an online community for patients, families and friends of those with heart disease, click here.

If you are a medical professional and would like to connect with a Mayo Clinic physician, click here.